2636 related articles for article (PubMed ID: 16014882)
1. Erlotinib in previously treated non-small-cell lung cancer.
Shepherd FA; Rodrigues Pereira J; Ciuleanu T; Tan EH; Hirsh V; Thongprasert S; Campos D; Maoleekoonpiroj S; Smylie M; Martins R; van Kooten M; Dediu M; Findlay B; Tu D; Johnston D; Bezjak A; Clark G; Santabárbara P; Seymour L;
N Engl J Med; 2005 Jul; 353(2):123-32. PubMed ID: 16014882
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
[TBL] [Abstract][Full Text] [Related]
3. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Wheatley-Price P; Ding K; Seymour L; Clark GM; Shepherd FA
J Clin Oncol; 2008 May; 26(14):2350-7. PubMed ID: 18467727
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
Lilenbaum R; Axelrod R; Thomas S; Dowlati A; Seigel L; Albert D; Witt K; Botkin D
J Clin Oncol; 2008 Feb; 26(6):863-9. PubMed ID: 18281658
[TBL] [Abstract][Full Text] [Related]
8. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Bezjak A; Tu D; Seymour L; Clark G; Trajkovic A; Zukin M; Ayoub J; Lago S; de Albuquerque Ribeiro R; Gerogianni A; Cyjon A; Noble J; Laberge F; Chan RT; Fenton D; von Pawel J; Reck M; Shepherd FA;
J Clin Oncol; 2006 Aug; 24(24):3831-7. PubMed ID: 16921034
[TBL] [Abstract][Full Text] [Related]
9. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
Gaafar RM; Surmont VF; Scagliotti GV; Van Klaveren RJ; Papamichael D; Welch JJ; Hasan B; Torri V; van Meerbeeck JP;
Eur J Cancer; 2011 Oct; 47(15):2331-40. PubMed ID: 21802939
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Smith J
Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
[TBL] [Abstract][Full Text] [Related]
12. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
Johnson BE; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Lin CY; Marsland T; Patel T; Polikoff J; Rubin M; White L; Yang JC; Bowden C; Miller V
J Clin Oncol; 2013 Nov; 31(31):3926-34. PubMed ID: 24101054
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
14. Efficacy vs. effectiveness: erlotinib in previously treated non-small-cell lung cancer.
Sheikh N; Chambers CR
J Oncol Pharm Pract; 2013 Sep; 19(3):228-36. PubMed ID: 23175450
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
Matsuura S; Inui N; Ozawa Y; Nakamura Y; Toyoshima M; Yasuda K; Yamada T; Shirai T; Suganuma H; Yokomura K; Suda T; Chida K
Jpn J Clin Oncol; 2011 Aug; 41(8):959-63. PubMed ID: 21715361
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials.
Gao H; Ding X; Wei D; Cheng P; Su X; Liu H; Aziz F; Wang D; Zhang T
Anticancer Drugs; 2011 Oct; 22(9):842-52. PubMed ID: 21808188
[TBL] [Abstract][Full Text] [Related]
17. FDA drug approval summary: erlotinib (Tarceva) tablets.
Cohen MH; Johnson JR; Chen YF; Sridhara R; Pazdur R
Oncologist; 2005 Aug; 10(7):461-6. PubMed ID: 16079312
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.
Gregorc V; Novello S; Lazzari C; Barni S; Aieta M; Mencoboni M; Grossi F; De Pas T; de Marinis F; Bearz A; Floriani I; Torri V; Bulotta A; Cattaneo A; Grigorieva J; Tsypin M; Roder J; Doglioni C; Levra MG; Petrelli F; Foti S; Viganò M; Bachi A; Roder H
Lancet Oncol; 2014 Jun; 15(7):713-21. PubMed ID: 24831979
[TBL] [Abstract][Full Text] [Related]
19. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
Salazar F; Molina MA; Sanchez-Ronco M; Moran T; Ramirez JL; Sanchez JM; Stahel R; Garrido P; Cobo M; Isla D; Bertran-Alamillo J; Massuti B; Cardenal F; Manegold C; Lianes P; Trigo JM; Sanchez JJ; Taron M; Rosell R
Lung Cancer; 2011 Apr; 72(1):84-91. PubMed ID: 20705357
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
